



Update of the ICUD–SIU International Consultation on Bladder Cancer 2018: urinary diversion

Oscar Rodríguez Faba¹ · Mark D. Tyson² · Walter Artibani³ · Bernard H. Bochner⁴ · Fiona Burkhard⁵ · Scott M. Gilbert⁶ · Tilman Kälble⁷ · Stephan Madersbacher⁸ · Roland Seiler⁹ · Ella C. Skinner¹⁰ · George Thalmann⁹ · Joachim Thüroff¹¹ · Peter Wiklund¹² · Richard Hautmann¹³ · Joan Palou¹

Received: 5 June 2018 / Accepted: 10 September 2018 / Published online: 20 September 2018
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Abstract

Purpose To provide a comprehensive overview and update of the joint consultation of the International Consultation on Urological Diseases (ICUD) and Société Internationale d’Urologie on Bladder Cancer Urinary Diversion (UD).

Methods A detailed analysis of the literature was conducted reporting on the different modalities of UD. For this updated publication, an exhaustive search was conducted in PubMed for recent relevant papers published between October 2013 and August 2018. Via this search, a total of 438 references were identified and 52 of them were finally eligible for analysis. An international, multidisciplinary expert committee evaluated and graded the data according to the Oxford System of Evidence-based Medicine.

Results The incidence of early complications has been reported retrospectively in the range of 20–57%. Unfortunately, only a few randomized controlled studies exist within the field of UD. Consequently, almost all studies used in this report are of level 3–4 evidence including expert opinion based on “first principles” research.

Conclusions Complications rates overall following RC and UD are significant, and when strict reporting criteria are incorporated, they are much higher than previously published. Complications can occur up to 20 years after surgery, emphasizing the need for lifelong follow-up. Progress has been made to prevent complications implementing robotic surgery and fast track protocols. Preoperative patient information, patient selection, surgical techniques, and careful postoperative follow-up are the cornerstones to achieve good results.

Keywords Urinary diversion · Radical cystectomy and complications · MIBC and urinary diversions

✉ Oscar Rodríguez Faba
orodriguez@fundacio-puigvert.es

¹ Urological Oncology Unit, Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, C/ Cartagena, 340-350, 08025 Barcelona, Spain

² Department of Urology, Mayo Clinic, Scottsdale, USA

³ Urology Clinic, Verona Integrated University Hospital, Verona, Italy

⁴ Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA

⁵ Department of Urology, Inselspital Bern, Bern, Switzerland

⁶ Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA

⁷ Urology and Pediatric Urology Clinic, Klinikum Fulda, Fulda, Germany

⁸ Urology Department, Kaiser-Franz-Josef Hospital, Vienna, Austria

⁹ Uro-Oncology and Prostate Centre, Department of Urology, Inselspital Bern, Bern, Switzerland

¹⁰ Urologic Oncology, Department of Urology, Stanford University, Stanford, USA

¹¹ Department of Urology, University Clinic Mannheim, Mannheim, Germany

¹² Department of Urology, Department of Molecular Medicine and Surgery, Karolinska University Hospital, Solna, Sweden

¹³ Department of Urology, University of Ulm, Ulm, Germany

Introduction

Radical cystectomy (RC) with urinary diversion (UD) is one of the most challenging procedures in Urological Surgery due to the technical complexity [1]. However, it remains the best surgical option for patients with muscle-invasive bladder cancer (MIBC). The three most common types of UD are incontinent and continent abdominal wall UD (Ileal or colonic conduit, ureterocutaneostomy, continent pouches), urethral diversions or neobladders and rectosigmoid diversions. Any form of UD has its specific problems. In this context, surgeons must continue to refine their surgical technique of RC and UD to provide the utmost safety for the patient. Moreover, it is important to constantly work to improve outcomes due to rising healthcare costs. We discuss the 3rd International Consultation on Bladder Cancer recommendations on the reconstructive options after RC, the criteria for selection of the most appropriate procedure, and the outcomes and complications associated with the available UD options.

Materials and methods

This is a non-systematic review to perform an update on UD in bladder cancer (BC). An international, multidisciplinary expert committee evaluated and graded the published data according to the Oxford System of Evidence-based Medicine [2]. The present analysis focused on the following topics (keywords): urinary diversion, radical cystectomy and complications, MIBC and urinary diversions. The preliminary results of this analysis were presented during a joint international consultation of the ICUD and Société Internationale d'Urologie held in Lisbon (Portugal) on October 2017, and its proceedings were later published in electronic book format. For this updated publication, an exhaustive search was conducted in PubMed for recent relevant papers published between October 2013 and August 2018 using upon mentioned topics as keywords. Via this search after further exclusion of records not related to this review, two independent authors (O.R.F and J.P) screened titles and abstracts of a total of 438 references. A total of 386 articles were excluded by to be unrelated articles, articles not fully addressing topics or repeated publications on the same cohort. Fifty-two of them were finally eligible for analysis.

Figure 1 provides the respective CONSORT diagram for the included studies. A summary of conclusions and recommendations is provided in Table 1.

Fig. 1 This CONSORT diagram outlines the selection process of the included studies




Table 1 Summary of conclusions and recommendations for urinary diversion

	LE	GR
When the terminal ileum is used, about a third of patients require vitamin B ₁₂ supplementation. Confirmed vitamin B ₁₂ deficiency requires lifelong supplementation	III	B
A regular endoscopic control in UST and cystoplasties are mandatory from the 5th postoperative year onward due to the higher risk to develop tumor (adenocarcinoma)	III	B
Patient selection and adherence to meticulous surgical technique can provide acceptable outcomes in irradiated patients who require diversion	III	B
Usually, implementation of the ERAS protocol has resulted in significantly reduced length of hospital stay and decreased cost with comparable rates of complications and readmission	II	B
OBS seems to provide better QoL outcomes than other UD's mainly in the short and mid term	II	B
Continence and voiding function following neobladder are determined primarily by characteristics of the reservoir and by a preserved, innervated outlet mechanism	II	B
Orthotopic neobladder reconstruction is an attractive option for selected women. Oncologic outcomes appear to be excellent with appropriate selection criteria	III	B
The most important advantages deriving from RARC were a reduction of blood loss and a shorter hospital stay, while operative time was shorter after ORC	II	B
While we are still waiting for stronger scientific evidence RARC with intracorporeal urinary diversion appears to be a viable alternative to an open operation, offering patients the advantages of a minimally invasive approach	III	C

RARC robot-assisted radical cystectomy, LE level of evidence, GR grade of recommendation

General aspects

Metabolic consequences

The metabolic consequences of UD may vary depending on the different bowel segments used. Loss of bowel length, reducing its absorptive capacity and the contact of urine with the bowel results in shift of electrolytes leading to metabolic changes. These are influenced by co-morbidities such as impaired renal and hepatic function, previous bowel resection, as well as by the patient's age. Moreover, the movement of water and electrolytes is impacted by the bowel segment used for diversion, the length of the bowel segment, the time that the urine is retained in the reservoir, the concentration of urinary solutes, urinary pH, and osmolality (Table 2).

Secondary tumors

Secondary tumors can be developed in 0.18–15% of patients after UD; Their frequency is higher after ureterosigmoidostomies (UST) and cystoplasties. The risk of colon tumor following UST is increased 8–550-fold compared to the general population, depending on the patient's age at the time of operation [3]. The latency period is shorter if the operation is performed because of malignant disease. It can be speculated that an adenoma–adenocarcinoma sequence exists for the secondary tumors similar to that observed in normal colon carcinogenesis [4]. Most experts suggest that a regular endoscopic control in UST and cystoplasties is mandatory from the 5th postoperative year onward, whereas in the case of neobladders, conduits,

and pouches it seems sufficient to perform endoscopy in the presence of symptoms such as hematuria or new onset of hydronephrosis.

Pelvic radiation and urinary diversion

Pelvic radiation may produce a damaging exposure of the cecum, appendix, and terminal ileum. Intraoperative inspection of the small and large intestine plays an important role in the selection of appropriate bowel segments for the desired reconstruction.

Bowel that shows thickening or fibrotic changes from prior radiation exposure should be avoided as the use of such segments may lead to poor healing and urinary leaks.

Initial recommendations for UD in patients who have received pelvic radiation included the preferred use of the transverse colon as a conduit [5]. Nevertheless, recent evidence suggests that ileum could be used safely with a similar complication risk to that observed with colonic conduits in the setting of prior pelvic radiation treatment [6]. It would seem from the cumulative evidence published to date that in properly selected patients orthotopic reconstruction can be performed with reasonable functional outcomes assuming 66–77% overall complications [7]. Although the follow-up was limited, it would appear that the neobladder can tolerate moderate levels of radiation (39.6–65 Gy) [8]. Salvage cystectomy after failed bladder-sparing therapy for MIBC is associated with acceptable morbidity, although complication rates are slightly higher than for other RC series [9].

Table 2 Summary of the advantages, disadvantages, and metabolic consequences after urinary diversion according to bowel segment

Bowel segment	Advantages	Disadvantages	Malabsorption and metabolic consequences	Treatment of metabolic consequences
Stomach	Least water permeability	Anatomic distance to the pelvic floor	Hypergastrinemia Vitamin B ₁₂ deficiency Hyponatremic hypochloremic alkalosis	PPIs or H ₂ blockers Irrigation of the bladder with bicarbonate Vitamin B ₁₂ supplementation ^a Fluid intake, carbonic acid, intravenous saline
Jejunum		Highest water permeability; not recommended for urinary diversions		
Ileum	No malabsorptive sequelae Rare pathologies that prevent its use Loss of significant length can be tolerated	Higher water permeability than the colonic wall	Dilute urine: hypovolemic, hypochloremic, hyperkalemic acidosis	Oral sodium bicarbonate, catheter drainage, Ringer lactate infusion
Terminal ileum	Length of the mesentery	Higher water permeability than the colonic wall Impact on small bowel transit time; increased stool frequency when resected	Vitamin B ₁₂ deficiency Dilute urine: hypovolemic, hypochloremic, hyperkalemic acidosis	Vitamin B ₁₂ supplementation ^a Oral sodium bicarbonate, catheter drainage, Ringer lactate infusion
Ileocecal valve		Regulates the small bowel transit time	Steatorrhea Vitamin B ₁₂ deficiency	Cholestyramine 3×4 g per day Vitamin B ₁₂ supplementation ^a
Colon	Less water-permeable than the ileal wall Proximity of the sigmoid colon to the pelvic floor No malabsorptive sequelae	Storage function of right-sided colon	Bile salt loss ^b Diarrhea ^b Vitamin B ₁₂ deficiency ^b Higher concentrated urine: hyperchloremic, hyperkalemic acidosis	Vitamin B ₁₂ supplementation ^a Oral sodium bicarbonate ^c , catheter drainage, ringer lactate infusion

PPIs proton pump inhibitors

^aLifelong supplementation required

^bMainly in cases of concomitant resection of the ileocecal valve and use of the right-sided colon

^cOr potassium citrate, in cases of hypokalemic acidosis

Pregnancy/sexual dysfunction after radical cystectomy and urinary diversion

The etiology of sexual dysfunction after UD is multifactorial, and although effective management options are available, broad awareness of the importance of these long-term consequences of cystectomy and UD have gained a firm footing only over the last several years. Nerve-sparing and organ-preserving approaches to surgery are the most effective strategies to avoid the constellation of complications that negatively affect sexual function and pregnancy [10].

Enhanced recovery after surgery (ERAS)

Originally described in the 1990s [10, 11], enhanced recovery after surgery (ERAS) pathways are standardized interdisciplinary protocols that are aimed at improving outcomes after surgery by minimizing variation in preoperative, perioperative, and postoperative best practice [11]. Key elements

in the preoperative pathway include education to ensure compliance, nutritional optimization, smoking cessation, functional rehabilitation, and carbohydrate loading. In the perioperative setting, some common elements include the prevention of hypothermia, judicious fluid management, venous thromboembolism prophylaxis (compression stocking, pneumatic compression, and prophylactic heparin), use of Alvimopan, and avoidance of opioid-based analgesics. Postoperatively, this includes avoidance of nasogastric tube decompression, early oral feeding, early drain removal, early ambulation, avoidance of narcotics through the use of Ketorolac, Acetaminophen, or regional blocks, and continued use of Alvimopan.

While there are several theoretical explanations for why ERAS protocols would improve outcomes, the evidence supporting their use in cystectomy patients is not consistently rooted in robust experimental data. This may explain why there is striking variation in both the magnitude and the direction of the effect of ERAS protocols on perioperative

outcomes [12]. Nevertheless, in a recent meta-analysis, ERAS reduced the length of the index hospitalization, lowered the rate of low-grade complications, and improved the time to bowel function without impacting overall readmission rates [12]. While these findings are compelling and seem to support the implementation of ERAS for cystectomy patients, they must be contextualized within the obvious limitation that most of these studies constituted low-level evidence. In lieu of a clinical trial, a natural experiment employing a difference-in-differences approach may be the next logical step as it would similarly offer relatively unbiased effect estimates while mitigating the confounding effect of contemporaneous changes to clinical care.

Quality of life (QoL) following urinary diversion

“Quality of life” is a construct that encompasses the physical, psychosocial, and functional health and reflects a patient satisfaction with various aspects of his/her life. To minimize bias, quality of life is most commonly assessed by standardized patient-reported survey instruments. Valid, reliable, longitudinal measurement of quality of life has important implications for research comparing treatment options as well as for delivery of patient-centered clinical care.

While there is little variation in general or disease-specific quality of life outcomes by urinary diversion type historically, emerging evidence from high-quality publications in the last few years has suggested that some important differences may exist. Whereas incontinent diversions have demonstrated greater improvement in physical health compared to continent diversions, continent diversions have shown superior emotional function and body image compared to cutaneous diversion [13, 14]. While there is sparse information regarding the effect of gender on quality of life after cystectomy, male patients seem to show better scores in the neobladder subgroup [13] and female patients exhibit no difference between ileal conduits and neobladders [15].

With respect to sexual function, some evidence has suggested improved outcomes with neobladders compared to ileal conduits [16]. Informed decision making remains the key factor for choice of diversion for patients undergoing cystectomy. Future patient-centered research is needed and has been identified as a priority for funding agencies.

Types of urinary diversion

Ileal conduit (IC)

Urinary conduit using ileum is the most commonly performed conduit procedure [17]. IC is indicated in patients who do not qualify for a continent diversion or do not want to comply with the inconveniences of a continent diversion.

In this context the physical and mental status, age, body habitus (obesity, malformations), extent of disease, prognosis, urethral involvement, kidney and liver function, and the patient’s expectations and preferences, as well as the surgeon’s experience and preference, often play an important role in the decision. A short-term complication highly relevant to IC is urine leak at the ureteroileal anastomosis, which occurs in 2–5.5% of patients [18].

This problem can be obviated by proper surgical technique and placement of ureteral stents. Two studies showed that stenting reduced the risk of early upper tract dilatation and was associated with improved bowel function [19, 20]. Madersbacher et al. analyzed all conduit-associated complications in 131 patients occurring later than 3 months after surgery. Sixty-six percent of patients had conduit-associated complications [21]. The most frequent complications were renal insufficiency (27%), problems with the stoma (24%), intestinal problems (24%), symptomatic upper urinary tract infections (23%), conduit and ureter anastomotic stenosis/strictures (14%), and urolithiasis (9%). In the first 5 years of their analysis, 45% of patients developed complications. This percentage increased over time to 50%, 54%, and 94% among patients who survived 10, 15, and over 15 years, respectively.

Orthotopic bladder substitution (OBS)

Although there is no age cut off for OBS, in practice many patients over the age of 80 years will opt for a conduit. While the reasons are not entirely clear, it is almost certainly related to increased comorbidities and worse overall health status in older patients. The motivation of the patient is the most important factor when considering the suitability for an OBS, although it is difficult to assess this objectively [22]. There are different techniques using ileal segments of OBS [23]. Our committee continues to consider a minimum annual hospital caseload of 25 surgeries, done by not more than two surgeons, to be the definition of a high-volume hospital. Surgical volume might be associated with better outcomes after RC [24].

Even in the most experienced hands, OBS is a morbid procedure, with contemporary single-institution series reporting postoperative complications in the range of 25–57%, in-hospital mortality of $\leq 3\%$, and reoperation rates in the range of 2.3–17% [25]. The disparity in the quality of surgical complication reporting in urologic oncology makes it impossible to compare the morbidity of surgical techniques and outcomes [26].

OBS reconstruction is also an attractive option for selected women undergoing RC for bladder cancer. Oncologic outcomes appear to be excellent with appropriate selection criteria. Urinary retention is clearly more common in women than men undergoing orthotopic diversion.

Retention can occur in the early postoperative period but often appears after an initial phase of good NB function and emptying [27]. In the Ulm series of 116 women, the rate of retention increased steadily over time to approximately 50% by 5 years [28].

Continent cutaneous diversion (CCD)

A variety of techniques for construction of a CCD have been described. All use detubularized segments of bowel using either the right colon, ileum, or a combination of the two, folded to form a spherical shape. The advantages of CCD over OBS include immediate continence and, once the reservoir has expanded, ability to void less frequently and often sleep through the night [29]. However, the disadvantages of CCD are a longer, more complex surgical procedure, absolute dependence on catheterization for emptying, and higher rates of late complications related to the efferent continence mechanism that often require surgery to resolve. Continence is usually immediate, though pouch volume will increase and pressure decrease during the initial few months. Because of the routine catheterization, bacterial colonization of the reservoir is the norm, and attempts to sterilize the urine are fruitless.

Many patients receive unnecessary antibiotics from primary care providers. However, febrile infections and even urosepsis do occur, especially in the early postoperative period. Reported rates of early and late febrile infections range from 20 to 40% [30], which is probably higher than with OBS or conduit.

Anal diversion

The Mainz pouch II is an adaptation of ureterosigmoidostomy through the addition of rectosigmoid pouch formation [31]. Briefly, the rectosigmoid colon is detubularized and reconfigured into a spherical shape to mitigate the risk of pyelonephritis and anal incontinence. Detubularization of these bowel segments interferes with bowel contractions thereby decreasing storage pressures and increasing capacity, improving urinary continence rates and upper tract preservation. A prerequisite for a successful continent anal diversion is a competent anal sphincter to control continence and allow spontaneous evacuation. Furthermore, coexistent large bowel pathology must be excluded by colonoscopy, computed tomography colonography, or conventional colonography with double contrast prior to surgery.

According to the published literature, daytime urinary continence is achieved in 98% and nighttime continence in 90% [32]. Early postoperative complications include urinary leakage and ileus in up to 30% as well as late complications such as pyelonephritis, ureteral implantation stenosis, and metabolic acidosis in up to 28%, ureter stenosis dilatation/

reimplantation in up to 11%, and the need for alkalinizing agents in up to 69% [32, 33]. Given the risk of secondary adenocarcinoma formation, indications for Mainz pouch II have over the years become restricted to older patients in whom the latency period until development of a colorectal tumor would exceed their life expectancy and to younger patients who will not accept a stoma for cultural, socioeconomic, or cosmetic reasons and would otherwise have no alternative for UD.

Robotic diversion

Globally the indications for robot-assisted radical cystectomy (RARC) with urinary diversion are identical to open radical cystectomy (ORC). Even in the most experienced hands, the rates of overall complications after cystectomy are high, reaching up to 64%, while the rates of Clavien ≥ 3 complications can be as high as 41% [34]. In systematic analyses, meta-analyses and large national health care registries it seems that there is a consistent pattern in complications and outcomes comparing RARC to ORC [35, 36]. RARC shows decreased blood loss, transfusion rates, length of stay (LOS) and overall complications, which may be expected from a minimally invasive procedure (Table 3). On the other hand, the operative times are longer for RARC as compared to ORC.

Blood loss and transfusion are classified as grade 2 complications in the Clavien–Dindo classification system and may be downplayed in complication reporting. However, blood loss leading to transfusion is a major predictor of worse oncological prognosis [37–39].

The most important advantages deriving from RARC were a reduction of blood loss and a shorter hospital stay, while operative time was shorter after ORC. Data about long-term functional and oncological outcomes are still lacking, nevertheless a recent randomised, phase III, non-inferiority trial (RAZOR study) concluded that RARC was not inferior to ORC for 2-year progression-free survival; Adverse events occurred in 101 (67%) of 150 patients in the RARC group and 105 (69%) of 159 patients in the ORC group [40].

There is a controversy on whether to perform an intracorporeal (ICUD) or extracorporeal urinary diversion (ECUD). Justifications for ECUD are a shorter operative time and the need for an extraction incision. ICUD presents important challenges included a longer operative time and a steeper learning curve as well as the number of technical challenges. One of the largest series reporting outcomes after ICUD describe a U-shaped neobladder technique and report 80–90% daytime continence rates with complication rates similar to open series [41]. A retrospective analysis of intracorporeal with ECUD including 935 patients who had RARC showed equivalent operative time and no difference

Table 3 Operative data on robot-assisted radical cystectomy compared to open radical cystectomy

Author	Year	Patients, <i>n</i>	Operation time (h)		Blood loss (cc)		LOS (days)	
			RARC	ORC	RARC	ORC	RARC	ORC
Wang et al. [37]	2015	54	6.5	6	400	750	5	8
Nix et al. [46]	2010	41	4.2	3.5	278	575	5	6
Parekh et al. [47]	2013	47	5	4.8	400	800	6	6
Khan et al. [48]	2012	100	6.4	5.3	337	1352	10	19
Richards et al. [49]	2012	70	7.7	6.1	275	600	7	14
Knox et al. [50]	2013	142	7.8	6.6	276	1522	6	11
Bochner et al. [51]	2015	118	7.6	5.5	516	676	8	8
Khan et al. [48]	2016	40	6.5	4.8	585	808	12	14
Hu et al. [52]	2016	1317	NR	NR	NR	NR	8	8
Parekh et al. [40]	2018	350	7.1	6	300	700	6	7

LOS length of stay, ORC open radical cystectomy, RARC robot-assisted radical cystectomy

in the reoperation rates. Patients with ICUD were at lower risk of experiencing postoperative complications [42]. While we are still waiting or stronger scientific evidence RARC with ICUD appears to be a viable alternative to an open operation, offering patients the advantages of a minimally invasive approach.

Palliative diversion

Palliative urinary diversion (UD) refers to the insertion of a double J ureteral catheter, a percutaneous nephrostomy (PCN), subcutaneous drainage, ileal conduits or ureterocutaneostomy. Consensus is lacking as to whether the initial attempt at a palliative UD should be made via ureteral stenting or PCN; however, the need for external urinary drainage devices with PCN may have quality of life implications.

Yet, the insertion of a ureteral double J stent is not always feasible because of extensive pelvic disease, anatomic deformities, bleeding, or ureteral compression. In a series of 186 patients, insertion of a ureteral double J catheter failed in 21% of patients [43].

As an alternative to conventional forms of palliative UD, a subcutaneous pyelovesical bypass was developed more than a decade ago. Desgrandchamps et al. reported on a series of 19 patients who received 27 subcutaneous tubes as a palliative UD [44]. All patients had a PCN as the initial form of diversion. At follow-up of about 6–8 months, the authors observed an improvement of the physical function scale (EORTC QLC-30) as a result of the elimination of the PCN and a parallel worsening of the symptom scale secondary to disease progression [44]. The authors concluded that the subcutaneous pyelovesical bypass provides a better QoL than a standard PCN in terminally ill patients by making them external tube free.

In summary, the survival of a patient undergoing palliative UD is dismal and in the range of 100 days [31, 45]. The decision to perform palliative UD should be approached

cautiously in patients with a poor performance status, low serum albumin levels, and other risk factors for rapid decompensation. Since the 6-month survival rate is less than 15%, and in some series even below 5%, the palliative UD in this setting needs to be an individualized decision discussed in a multidisciplinary approach with a medical oncologist.

Conclusions

Complications rates overall following RC and UD are significant, and when strict reporting criteria are incorporated, they are much higher than previously published. Complications can occur up to 20 years after surgery, emphasizing the need for lifelong follow-up. Progress has been made to prevent complications implementing robotic surgery and fast-track protocols. Preoperative patient information, patient selection, surgical techniques, and careful postoperative follow-up are the cornerstones to achieve good results. Increased adoption of robotic technology in surgery should lead to future randomised trials across different organ sites to assess the true clinical value provided by novel technology. The International Consultation on Urological Diseases (ICUD) has looked at the published evidence and produced recommendations at various levels.

Author contributions Protocol/project development: ORF, MDT, JP, RH. Data collection or management: all authors. Data analysis: ORF, JP, RH. Manuscript writing/editing: all authors.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Research involving human participants and/or animals For this type of study formal consent is not required. This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent Informed consent was obtained from all individual participants included in the study.

References

- Hautmann RE, Abol-Enein H, Lee CT et al (2015) Urinary diversion: how experts divert. *Urology* 85:233–238
- Philips B, Ball C, Sackett D et al (2009) Oxford centre for evidence-based medicine—levels of evidence (March 2009). <http://www.cebm.net/oxford-centre-evidence-based-medicine-level-s-evidence-march-2009/>
- Kalble T, Tricker AR, Friedl P et al (1990) Ureterosigmoidostomy: long-term results, risk of carcinoma and etiological factors for carcinogenesis. *J Urol* 144:1110–1114
- Kalble T, Hofmann I, Riedmiller H et al (2011) Tumor growth in urinary diversion: a multicenter analysis. *Eur Urol* 60:1081–1086
- Ravi R, Dewan AK, Pandey KK (1994) Transverse colon conduit urinary diversion in patients treated with very high dose pelvic irradiation. *Br J Urol* 73:51–54
- Fontenot PA Jr, Barnes BD, Parker WP et al (2018) Postoperative outcomes after radical cystectomy in patients with prior pelvic radiation. *Urology* 116:131–136
- Shabsigh A, Korets R, Vora KC et al (2009) Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. *Eur Urol* 55:164–174
- Ballas L, Sargos P, Orre M et al (2017) Tolerance of orthotopic ileal neobladders to radiotherapy: a multi-institutional retrospective study. *Clin Genitourin Cancer* 15:711–716
- Eswara JR, Efstathiou JA, Heney NM et al (2012) Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. *J Urol* 187:463–468
- Volkmer BG, Gschwend JE, Herkommer K et al (2004) Cystectomy and orthotopic ileal neobladder: the impact on female sexuality. *J Urol* 172:2353–2357
- Kehlet H (1997) Multimodal approach to control postoperative pathophysiology and rehabilitation. *Br J Anaesth* 78:606–617
- Tyson MD, Chang SS (2016) Enhanced recovery pathways versus standard care after cystectomy: a meta-analysis of the effect on perioperative outcomes. *Eur Urol* 70:995–1003
- Cerruto MA, D’Elia C, Siracusano S et al (2016) Systematic review and meta-analysis of non RCT’s on health related quality of life after radical cystectomy using validated questionnaires: better results with orthotopic neobladder versus ileal conduit. *Eur J Surg Oncol* 42:343–360
- Yang LS, Shan BL, Shan LL et al (2016) A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. *Surg Oncol* 25:281–297
- Gacci M, Saleh O, Cai T et al (2013) Quality of life in women undergoing urinary diversion for bladder cancer: results of a multicenter study among long-term disease-free survivors. *Health Qual Life Outcomes* 11:43
- Mansson A, Davidsson T, Hunt S et al (2002) The quality of life in men after radical cystectomy with a continent cutaneous diversion or orthotopic bladder substitution: is there a difference? *BJU Int* 90:386–390
- Lee RK, Abol-Enein H, Artibani W et al (2014) Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. *BJU Int* 113:11–23
- Somani BK, Gimlin D, Fayers P et al (2009) Quality of life and body image for bladder cancer patients undergoing radical cystectomy and urinary diversion—a prospective cohort study with a systematic review of literature. *Urology* 74:1138–1143
- Mattei A, Birkhaeuser FD, Baermann C et al (2008) To stent or not to stent perioperatively the ureteroileal anastomosis of ileal orthotopic bladder substitutes and ileal conduits? Results of a prospective randomized trial. *J Urol* 179:582–586
- Yong SM, Dublin N, Pickard R et al (2003) Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. *Cochrane Database Syst Rev* 2:CD003306
- Madersbacher S, Schmidt J, Eberle JM et al (2003) Long-term outcome of ileal conduit diversion. *J Urol* 169:985–990
- Nieuwenhuijzen JA, de Vries RR, Bex A et al (2008) Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions. *Eur Urol* 53:834–842 (**discussion 842–834**)
- Burkhard FC, Kessler TM, Springer J et al (2006) Early and late urodynamic assessment of ileal orthotopic bladder substitutes combined with an afferent tubular segment. *J Urol* 175:2155–2160 (**discussion 2160–2151**)
- Waingankar N, Mallin K, Smaldone M et al (2017) Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy. *BJU Int* 120:239–245
- Hautmann RE, de Petriconi RC, Volkmer BG (2011) 25 years of experience with 1,000 neobladders: long-term complications. *J Urol* 185:2207–2212
- Studer UE, Danuser H, Thalmann GN et al (1996) Antireflux nipples or afferent tubular segments in 70 patients with ileal low pressure bladder substitutes: long-term results of a prospective randomized trial. *J Urol* 156:1913–1917
- Gross T, Meierhans Ruf SD, Meissner C et al (2015) orthotopic ileal bladder substitution in women: factors influencing urinary incontinence and hypercontinence. *Eur Urol* 68:664–671
- Hautmann RE, Volkmer BG, Schumacher MC et al (2006) Long-term results of standard procedures in urology: the ileal neobladder. *World J Urol* 24:305–314
- Elshal AM, Abol-Enein H, Mosbah A et al (2012) Serous-lined unidirectional valve for construction of continent cutaneous urinary reservoir: the test of time. *Urology* 80:452–458
- Nazmy M, Yuh B, Kawachi M et al (2014) Early and late complications of robot-assisted radical cystectomy: a standardized analysis by urinary diversion type. *J Urol* 191:681–687
- Ishioka J, Kageyama Y, Inoue M et al (2008) Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. *J Urol* 180:618–621 (**discussion 621**)
- Gilja I, Kovacic M, Radej M et al (1996) The sigmoidorectal pouch (Mainz pouch II). *Eur Urol* 29:210–215
- Gerharz EW, Kohl UN, Weingartner K et al (1998) Experience with the Mainz modification of ureterosigmoidostomy. *Br J Surg* 85:1512–1516
- Hautmann RE, Abol-Enein H, Davidsson T et al (2013) ICUD–EAU International Consultation on Bladder Cancer 2012: urinary diversion. *Eur Urol* 63:67–80
- Li K, Lin T, Fan X et al (2013) Systematic review and meta-analysis of comparative studies reporting early outcomes after robot-assisted radical cystectomy versus open radical cystectomy. *Cancer Treat Rev* 39:551–560
- Leow JJ, Reese S, Trinh QD et al (2015) Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis. *BJU Int* 115:713–721
- Wang YL, Jiang B, Yin FF et al (2015) Perioperative blood transfusion promotes worse outcomes of bladder cancer after radical cystectomy: a systematic review and meta-analysis. *PLoS One* 10:e0130122
- Abel EJ, Linder BJ, Bauman TM et al (2014) Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? *Eur Urol* 66:1139–1147

39. Kretschmer A, Grimm T, Buchner A et al (2017) Prospective evaluation of health-related quality of life after radical cystectomy: focus on peri- and postoperative complications. *World J Urol* 35:1223–1231
40. Parekh DJ, Reis IM, Castle EP et al (2018) Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. *Lancet* 391:2525–2536
41. Tyrirtzis SI, Hosseini A, Collins J et al (2013) Oncologic, functional, and complications outcomes of robot-assisted radical cystectomy with totally intracorporeal neobladder diversion. *Eur Urol* 64:734–741
42. Ahmed K, Khan SA, Hayn MH et al (2014) Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. *Eur Urol* 65:340–347
43. Izumi K, Mizokami A, Maeda Y et al (2011) Current outcome of patients with ureteral stents for the management of malignant ureteral obstruction. *J Urol* 185:556–561
44. Desgrandchamps F, Leroux S, Ravery V et al (2007) Subcutaneous pyelovesical bypass as replacement for standard percutaneous nephrostomy for palliative urinary diversion: prospective evaluation of patient's quality of life. *J Endourol* 21:173–176
45. Shekarriz B, Shekarriz H, Upadhyay J et al (1999) Outcome of palliative urinary diversion in the treatment of advanced malignancies. *Cancer* 85:998–1003
46. Nix J, Smith A, Kurpad R et al (2010) Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. *Eur Urol* 57:196–201
47. Parekh DJ, Messer J, Fitzgerald J et al (2013) Perioperative outcomes and oncologic efficacy from a pilot prospective randomized clinical trial of open versus robotic assisted radical cystectomy. *J Urol* 189:474–479
48. Khan MS, Gan C, Ahmed K et al (2016) A single-centre early phase randomised controlled three-arm trial of open, robotic, and laparoscopic radical cystectomy (CORAL). *Eur Urol* 69:613–621
49. Richards KA, Kader AK, Otto R et al (2012) Is robot-assisted radical cystectomy justified in the elderly? A comparison of robotic versus open radical cystectomy for bladder cancer in elderly ≥ 75 years old. *J Endourol* 26:1301–1306
50. Knox ML, El-Galley R, Busby JE (2013) Robotic versus open radical cystectomy: identification of patients who benefit from the robotic approach. *J Endourol* 27:40–44
51. Bochner BH, Dalbagni G, Sjoberg DD et al (2015) Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. *Eur Urol* 67:1042–1050
52. Hu JC, Chughtai B, O'Malley P et al (2016) Perioperative outcomes, health care costs, and survival after robotic-assisted versus open radical cystectomy: a national comparative effectiveness study. *Eur Urol* 70:195–202